Brief Article
Copyright ©2011 Baishideng Publishing Group Co.
World J Hepatol. Nov 27, 2011; 3(11): 278-284
Published online Nov 27, 2011. doi: 10.4254/wjh.v3.i11.278
Table 3 Results of antiviral treatment in patients with low grade B cell-non Hodgkin’s lymphoma
SexAge (yr)HistologyStageHCVRNA log10 (UI/mL)GenotypeStaging (Ishak)TreatmentTreatment duration (mo)Response to treatmentRemission lymphoma
1F70Marginal extranodalIV5.92a/2c0Peg 180 μg/wk + RBV 800 mg/d6SVRComplete hematological response
2F69Marginal extranodalIV5.42a6Peg 180 μg/wk + RBV 800 mg/d6SVRComplete hematological response
3F64Marginal extranodalIV5.61bndPeg 180 μg/wk + RBV 1000 mg/d12RelapserProgressive disease
4M36Marginal splenicIV5.521Peg 180 μg/wk + RBV 800 mg/d6SVRPartial response
5F72Marginal splenicIII6.01b2Peg 180 μg/wk + RBV 1000 mg/d12SVRPartial response
6F65Marginal splenicIV5.62a/2cndPeg 180 μg/wk + RBV 1200 mg/d6SVRComplete hematological response
7F70Marginal nodalIV5.922Peg 180 μg/wk + RBV 800 mg/d6SVRComplete hematological response
8F55Follicular lymphomaIII5.02a/2c6Peg 180 μg/wk + RBV 800 mg/d6RelapserProgressive disease
9M67Follicular lymphomaIV6.82a0Peg 180 μg/wk + RBV 800 mg/d6SVRComplete hematological response